CSIMarket
 


Eagle Pharmaceuticals inc   (EGRX)
Other Ticker:  
 

Eagle Pharmaceuticals Inc 's Long Term Debt to Equity

EGRX's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


Due to long-term debt repayement of -10.07% Eagle Pharmaceuticals Inc improved Long Term Debt to Equity in second quarter 2023 to 0.25, above the Eagle Pharmaceuticals Inc 's average Long Term Debt to Equity.

Within Major Pharmaceutical Preparations industry in the second quarter 2023, 52 other companies have achieved lower Long Term Debt to Equity than Eagle Pharmaceuticals Inc in the II Quarter 2023. While Long Term Debt to Equity total ranking has improved so far in the second quarter 2023 to 933, from total ranking in the first quarter 2023 at 1086 .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt EGRX´s has?
What is the structure of EGRX´s Equity?


EGRX Long Term Debt to Equity (Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Equity Change 5.91 % 12.45 % 32.36 % 25.09 % 22.14 %
Y / Y Long Term Debt Change 120.92 % - - 35.62 % 31.1 %
Long Term Debt to Equity MRQ 0.25 0.28 0.24 0.11 0.12
EGRX's Total Ranking # 933 # 1086 # 1066 # 710 # 706
Seq. Equity Change 3.79 % 3.98 % 0.77 % -2.61 % 10.2 %
Seq. Long Term Debt Change -10.07 % 22.44 % 112.69 % -5.66 % -



Long Term Debt to Equity second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 53
Healthcare Sector # 130
Overall Market # 933


Long Term Debt to Equity Statistics
High Average Low
0.28 0.19 0.11
(Mar 31 2023)   (Sep 30 2021)




Financial Statements
Eagle Pharmaceuticals Inc 's Equity $ 252 Millions Visit EGRX's Balance sheet
Eagle Pharmaceuticals Inc 's Long Term Debt $ 62 Millions Visit EGRX's Balance sheet
Source of EGRX's Sales Visit EGRX's Sales by Geography


Cumulative Eagle Pharmaceuticals Inc 's Long Term Debt to Equity

EGRX's Long Term Debt to Equity for the trailling 12 Months

EGRX Long Term Debt to Equity

(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Equity TTM Growth 5.91 % 12.45 % 32.36 % 25.09 % 22.14 %
Y / Y Long Term Debt TTM Growth 120.92 % - - 35.62 % 31.1 %
Long Term Debt to Equity TTM 0.22 0.19 0.12 0.06 0.06
Total Ranking TTM # 62 # 47 # 36 # 102 # 0
Seq. Equity TTM Growth 3.79 % 3.98 % 0.77 % -2.61 % 10.2 %
Seq. Long Term Debt TTM Growth -10.07 % 22.44 % 112.69 % -5.66 % -


On the trailing twelve months basis Despite of the long-term debt repayement of -10.07% in the trailing twelve months ending in II Quarter 2023, Long Term Debt to Equity improved to 0.22, above Eagle Pharmaceuticals Inc 's average Long Term Debt to Equity.
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 5, during the past 12 months, other companies have achieved lower Long Term Debt to Equity than Eagle Pharmaceuticals Inc . While Long Term Debt to Equity total ranking has deteriorated during the twelve months ending in the II Quarter 2023, compared to the prior period, from 47 to 62.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt EGRX´s has?
What is the structure of EGRX´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 6
Healthcare Sector # 16
Within the Market # 62


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
0.23 0.15 0.05
(Jun 30 2018)   (Mar 31 2022)




Companies with similar Long Term Debt to Equity in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Long Term Debt to EquityJun 30 2023 MRQ Long Term DebtJun 30 2023 MRQ Equity
Pacira Biosciences inc   0.66 $ 532.183  Millions$ 807.975  Millions
Axsome Therapeutics Inc   0.63 $ 176.820  Millions$ 278.804  Millions
Royalty Pharma Plc  0.62 $ 6,127.074  Millions$ 9,813.686  Millions
Pfizer Inc  0.62 $ 61,356.000  Millions$ 99,293.000  Millions
Viracta Therapeutics Inc   0.61 $ 25.077  Millions$ 40.782  Millions
Rani Therapeutics Holdings Inc   0.61 $ 29.265  Millions$ 48.169  Millions
Scpharmaceuticals Inc   0.60 $ 37.741  Millions$ 63.427  Millions
Maravai Lifesciences Holdings Inc   0.58 $ 520.336  Millions$ 897.638  Millions
Societal Cdmo Inc   0.57 $ 31.010  Millions$ 54.318  Millions
Syros Pharmaceuticals Inc   0.56 $ 40.930  Millions$ 73.239  Millions
Lexicon Pharmaceuticals Inc   0.53 $ 98.772  Millions$ 186.361  Millions
Rockwell Medical inc   0.50 $ 4.740  Millions$ 9.528  Millions
Blueprint Medicines Corporation  0.48 $ 150.556  Millions$ 311.130  Millions
Horizon Therapeutics Public Limited Company  0.48 $ 2,541.458  Millions$ 5,310.959  Millions
Emergent Biosolutions Inc   0.47 $ 448.000  Millions$ 956.300  Millions
Johnson and Johnson  0.44 $ 33,901.000  Millions$ 76,409.000  Millions
Verastem inc   0.39 $ 39.739  Millions$ 101.591  Millions
Abbott Laboratories  0.39 $ 14,562.000  Millions$ 37,404.000  Millions
Dynavax Technologies Corporation  0.38 $ 222.134  Millions$ 577.205  Millions
Aytu Biopharma Inc   0.37 $ 14.713  Millions$ 39.357  Millions
Harmony Biosciences Holdings inc   0.37 $ 180.487  Millions$ 485.172  Millions
Soligenix inc   0.36 $ 2.094  Millions$ 5.800  Millions
Cumberland Pharmaceuticals Inc  0.36 $ 13.148  Millions$ 36.837  Millions
Blue Water Biotech Inc   0.35 $ 4.537  Millions$ 13.076  Millions
Biovie Inc   0.34 $ 5.227  Millions$ 15.340  Millions
Werewolf Therapeutics Inc   0.33 $ 39.142  Millions$ 118.599  Millions
Inozyme Pharma Inc   0.30 $ 31.877  Millions$ 105.593  Millions
Savara Inc   0.30 $ 26.213  Millions$ 87.715  Millions
Roivant Sciences Ltd   0.29 $ 385.069  Millions$ 1,334.139  Millions
Uniqure N v   0.29 $ 101.110  Millions$ 353.320  Millions

Date modified: 2023-08-11T06:01:28+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com